DPV + LNG Vaginal Ring
Alternative Name: Dapivirine (DPV) + levonorgestrel (LNG) vaginal ring
Description: A silicone intravaginal ring (IVR) that a woman inserts and leaves in place for 90 days. The ring releases a combination of dapivirine, a non-nucleoside reverse transcriptase inhibitor (NNRTI), to prevent HIV and levonorgestrel, a synthetic progestin, to prevent unintended pregnancy.
Product Details
User: Female
Hormonal: Yes
Delivery Method: Vaginal Ring
Duration Type: Long-acting
Duration: 90 days
Active Pharmaceutical Ingredient (API): - dapivirine
- levonorgestrel
- dapivirine
- levonorgestrel
Inactive material: silicone
Multipurpose Preventive Technology (MPT): Yes
Status Details
Developer: International Partnership for Microbicides, USAID
Project Phase: Pre-Clinical and Clinical Development
Development Stage: Phase I
Active Development: Yes
Status Details: - In collaboration with the NIH-funded Microbicide Trials Network (MTN), a U.S.-based Phase I trial was completed in August, 2017 and another phase I trial is currently underway.
- In collaboration with the NIH-funded Microbicide Trials Network (MTN), a U.S.-based Phase I trial was completed in August, 2017 and another phase I trial is currently underway.
Additional Information
References: International Partnership for Microbicides website: https://www.ipmglobal.org/
Clinicaltrials.gov Identified NCT02855346
Clinicaltrials.gov Identified NCT03467347
Press Release: https://www.ipmglobal.org/content/ipm-advances-three-month-hiv-preventio...
International Partnership for Microbicides website: https://www.ipmglobal.org/
Clinicaltrials.gov Identified NCT02855346
Clinicaltrials.gov Identified NCT03467347
Press Release: https://www.ipmglobal.org/content/ipm-advances-three-month-hiv-preventio...